Charles Karim Bensalah

Hôpital Pontchaillou

Papers

1

Total Citations

25

H-Index

1

About

Charles Karim Bensalah is a leading urologic oncologist whose research focuses on the surgical management of kidney cancer, particularly through minimally invasive techniques. His major contributions center on comparing the efficacy and safety of percutaneous tumor ablation versus robotic-assisted partial nephrectomy for T1b renal cell carcinoma, as demonstrated in his landmark multicenter study, the AblatT1b trial (UroCCR 80). This matched-pair analysis, published in 2023 and already garnering 25 citations, provides critical evidence guiding treatment decisions for patients with larger renal tumors. Bensalah’s work has significantly advanced the field by clarifying the outcomes of these competing approaches, helping to optimize patient selection and surgical planning. His research is highly influential among urologists and oncologists, shaping clinical guidelines and improving patient care. Beyond this study, Bensalah has contributed extensively to the literature on renal cell carcinoma, with a strong track record of collaborative, multi-institutional research that underscores his role as a key opinion leader in urologic oncology.

Research Focus

Key Achievements

1
H-Index
1
Papers
25
Total Citations
25
Avg Citations/Paper
🏆 Most Cited Paper
A multicenter comparative matched-pair analysis of percutaneous tumor ablation and robotic-assisted partial nephrectomy of T1b renal cell carcinoma (AblatT1b study—UroCCR 80)
25 citations · 2023
📈 Most Prolific Year: 2023 (1 Papers)
🤝 Key Collaborators: 20
🏛 Institutions: Hôpital Pontchaillou

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago